PAREXEL Experts to Present Advanced Approaches to Accelerate Development, Maximize Product Value at DIA EuroMeeting

BOSTON, March 7, 2011 /PRNewswire/ -- Through various presentations to be delivered at the Drug Information Association (DIA) 23rd Annual EuroMeeting, being held March 28-30, 2011 in Geneva, Switzerland, experts from PAREXEL International Corporation (Nasdaq: PRXL), a leading global biopharmaceutical services provider, will address advanced approaches to help the biopharmaceutical industry meet demands of a changing global marketplace.

Experts from PAREXEL will be available at Stands 1050, 1052, 1151, and 1153 in the exhibit hall to discuss how the Company can help biopharmaceutical companies improve early-stage decisions, accelerate pivotal trials, reach new markets, and leverage technologies for increased operational quality and efficiency.  PAREXEL experts will discuss new operational models, supported by technology, to help its clients achieve greater benefits and speed development.

The DIA EuroMeeting program features the following presentations by PAREXEL experts, which address the benefits of combined clinical and technology expertise to enable more effective information flow and improved data access for greater visibility into trials – and ultimately, better decision making:

Tuesday, March 29

• Session 1, 9:00: Use of Electronic Health Records for Clinical Research, Isabelle de Zegher, Worldwide Senior Director Technology Integration and Data Standards

Wednesday, March 30

• Session 5, 9:00: How to Go Effectively from Data Collection in CDASH to Submission in SDTM: The need for an eCRF library, Isabelle de Zegher, Worldwide Senior Director Technology Integration & Data Standards
• Session 6, 11:00: Using Technology to Improve the Clinical Trial Process, Liz Love, Product Manager
• Session 8, 16:00: Simplicity (for sites) is the Ultimate Sophistication, Nikki Dowlman, Product Director

Poster Session:

"Key Regulatory and Market Access Considerations: Gaining the Right Perspective for Regional and Global Development and Commercialization," which has a focus on the Asia/Pacific region, will provide insights to assist biopharmaceutical companies with strategic approaches to product development and commercialization, as well as to demonstrate product value to patients, payers, and providers, particularly in emerging high growth markets.

Special Presentation:

"Knowledge Management Enablers – Operational and Quality Control Centres," to be presented by Siegfried Schmitt, Ph.D., Principal Consultant, in Session 8 on Wednesday, March 30 at 16:00, will reinforce key Quality by Design (QbD) concepts. Dr. Schmitt will provide timely background and practical advice as regulators move forward on joint QbD pilot reviews and increase efforts toward regional harmonization.

For more information about PAREXEL visit www.PAREXEL.com or Stands 1050, 1052, 1151, and 1153 during the meeting. Information about the 23rd Annual DIA EuroMeeting can be found at http://www.diahome.org.

About PAREXEL International

PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement.  Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process.  Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 52 countries around the world, and has approximately 10,380 employees. For more information about PAREXEL International visit www.PAREXEL.com.

This release contains "forward-looking" statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand.   For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements.  Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "will," "would," "could," "targets," and similar expressions are also intended to identify forward-looking statements.  The forward-looking statements in this release involve a number of risks and uncertainties.  The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release.  Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings, the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug,  medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks.   Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the quarter ended December 31, 2010 as filed with the SEC on February 9, 2011, which "Risk Factors" discussion is incorporated by reference in this press release.  The Company specifically disclaims any obligation to update these forward-looking statements in the future.  These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.

SOURCE PAREXEL International Corporation

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED